Seeking Alpha

William Blair initiates coverage on Savient Pharmaceuticals (SVNT) and Ardea Biosciences (RDEA),...

William Blair initiates coverage on Savient Pharmaceuticals (SVNT) and Ardea Biosciences (RDEA), citing their roles in developing therapies for gout. The firm estimates the U.S. gout market at $2B-$3B; SVNT's Krystexxa will start to gain traction this year, and RDEA's lesinurad, currently in Phase III studies with data expected in 2013, eventually will hit $1.7B in worldwide sales.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs